William K. Oh
| William K. Oh, M.D. | |
|---|---|
| Education | Yale University, NYU |
|
Medical career | |
| Profession | medical oncologist |
| Institutions |
Harvard Medical School Mount Sinai Medical Center |
| Specialism | genitourinary oncology |
| Research | cancer research |
William K. Oh, M.D., is an American medical oncologist and expert in the management of genitourinary malignancies, including prostate, renal, bladder and testicular cancers.
Oh is Chief of the Division of Hematology and Medical Oncology at The Mount Sinai Medical Center in New York City, Associate Director for Clinical Research at Mount Sinai's Tisch Cancer Institute, Professor of Medicine and Urology and the Ezra M. Greenspan, M.D., Professor in Clinical Cancer Therapeutics at The Mount Sinai School of Medicine.[1][2]
In 2009, Oh presented at the American Society of Clinical Oncology the findings of a two-year study which showed that a six-gene molecular diagnostic test, when combined with a PSA test, improved to 90% the accuracy of prostate cancer detection over PSA tests alone.[3]
Oh is the author of more than 180 articles and 70 abstracts. He is the editor of 3 books and the author of 18 book chapters. He has been listed in Castle Connolly’s "America’s Top Doctors for Cancer" from 2008 to 2011, "Best Doctors in America" from 2003 to 2011, was listed among Boston Magazine’s "Top Doctors" in 2005 and 2009 and New York Magazine's "Top Doctors" in 2010.[1][4]
Biography
Oh earned a B.S. from Yale University in 1987 and his M.D. from New York University School of Medicine in 1992. He completed an internship and a residency at Brigham and Women's Hospital in Boston and a clinical fellowship at the Dana–Farber Cancer Institute.
From 1997 to 2009, Oh served on the faculty of Harvard Medical School, where he was named Associate Professor of Medicine in 2007. In 2009, he joined The Mount Sinai Medical Center as the Ezra M. Greenspan Professor in Clinical Cancer Therapeutics and Professor of Medicine and Urology, as well as Chief of the Division of Hematology and Medical Oncology in Mount Sinai's Department of Medicine.[1]
Oh is a leading member of the American Society of Clinical Oncology. He has served on multiple editorial boards including the journals The Prostate, Clinical Genitourinary Cancer, the American Journal of Hematology and Oncology and CA – A Cancer Journal for Clinicians.
Oh has been the principal investigator on multiple clinical trials of chemotherapy in castration-resistant (CRPC) prostate cancer[5][6] and for three trials of neoadjuvant chemotherapy in high-risk localized prostate cancer patients.
At the Dana–Farber Cancer Institute, from 2000 to 2009, Oh developed and managed a prospective clinical database linked to blood and tissue banks for more than 8,000 prostate cancer patients, with links to blood samples and tissue repositories, for exploration of research and prognostic applications, including: efficacy of various therapies in CRPC, hormonal therapy, testosterone as a marker for cancer outcome, relapse predictions based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score.[7]
Honors and awards
1992 Alpha Omega Alpha[8]
1992 Prize in Internal Medicine, NYU School of Medicine
1997 ASCO/AACR Methods in Clinical Cancer Research Workshop[8]
2003 Compassionate Caregiver of the Year, Kenneth B. Schwartz Center, Honorable Mention
2003–present, Best Doctors in America
2004 Award Recipient, Loan Repayment Program for Clinical Research, NIH
2004–present, Who’s Who in America
2005 2009 Boston Magazine "Top Doctors"
2007-2008 Brigham/Harvard Business School Physician Leadership Program
2008–present, America’s Top Doctors for Cancer (Castle Connolly)
2010 Prostate Cancer Foundation Creativity Award
2010 New York Magazine "Top Doctors"
2011 Election to the American Society of Clinical Investigation
Grants
Oh has completed 16 grants. Active grants for which he is currently principal investigator or co-investigator include:
| Funding Source | Title | Description |
|---|---|---|
| NIH/NCI (P 50 CA90381) | DF/HCC SPORE in Prostate Cancer | Core 3: A major aim of the pathology core is to provide a tissue and blood repository for use by SPORE investigators. Project 4 is evaluating the role of hsp90 inhibitors in prostate cancer |
| Genentech /Sanofi-Aventis | A phase II study of neoadjuvant docetaxel plus bevacizumab in high risk localized prostate cancer patients | |
Publications
Partial list (of over 180):
- Oh WK, Halabi S, Kelly WK, et al. (December 2003). "A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813". Cancer 98 (12): 2592–8. doi:10.1002/cncr.11829. PMID 14669278.
- Oh WK, Kantoff PW, Weinberg V, et al. (September 2004). "Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer". J. Clin. Oncol. 22 (18): 3705–12. doi:10.1200/JCO.2004.10.195. PMID 15289492.
- Oh WK, Hagmann E, Manola J, et al. (January 2005). "A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer". Clin. Cancer Res. 11 (1): 284–9. PMID 15671557.
- Febbo PG, Richie JP, George DJ, et al. (July 2005). "Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer". Clin. Cancer Res. 11 (14): 5233–40. doi:10.1158/1078-0432.CCR-05-0299. PMID 16033841.
- Oh WK, Hayes J, Evan C, et al. (June 2006). "Development of an integrated prostate cancer research information system". Clin Genitourin Cancer 5 (1): 61–6. doi:10.3816/CGC.2006.n.019. PMID 16859581.
- Ross RW, Beer TM, Jacobus S, et al. (February 2008). "A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel". Cancer 112 (3): 521–6. doi:10.1002/cncr.23195. PMID 18085595.
- Ross RW, Xie W, Regan MM, et al. (March 2008). "Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect". Cancer 112 (6): 1247–53. doi:10.1002/cncr.23304. PMID 18293426.
- Ross RW, Oh WK, Xie W, et al. (February 2008). "Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer". J. Clin. Oncol. 26 (6): 842–7. doi:10.1200/JCO.2007.13.6804. PMID 18281655.
- Chan JM, Oh WK, Xie W, et al. (August 2009). "Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer". J. Clin. Oncol. 27 (22): 3577–83. doi:10.1200/JCO.2008.18.8938. PMC 2720077. PMID 19528373.
- Regan MM, O'Donnell EK, Kelly WK, et al. (February 2010). "Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials". Ann. Oncol. 21 (2): 312–8. doi:10.1093/annonc/mdp308. PMC 2852201. PMID 19633053.
- Oh WK, Hu J (February 2010). Prostate Cancer: "Advances and Controversies in Prostate Cancer.". Urologic Clinics of North America 37. pp. 1–148. doi:10.1016/j.ucl.2010.01.001. ISBN 978-1-4377-1916-1.
- Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL (March 2010). "Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?". Urology 75 (3): 642–7. doi:10.1016/j.urology.2009.08.008. PMID 19962733.
- Oh WK, Vargas R, Jacobus S, et al. (February 2011). "Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients". Cancer 117 (3): 517–25. doi:10.1002/cncr.25394. PMID 20862742.
- Anees M, Horak P, El-Gazzar A, et al. (March 2011). "Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression". Cancer 117 (6): 1172–82. doi:10.1002/cncr.25504. PMID 21381010.
References
- 1 2 3 "Mount Sinai Medical Center - Doctor profile".
- ↑ "Zoom Info: William Oh".
- ↑ "New blood test greatly reduces false-positives in prostate cancer screenings – Dana-Farber Cancer Institute".
- ↑ "Castle Connolly Medical Ltd.".
- ↑ Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP (November 2009). "Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer". Clin. Cancer Res. 15 (22): 7099–105. doi:10.1158/1078-0432.CCR-09-1722. PMID 19887483.
- ↑ "Dana-Farber Cancer Institute Oncologists Present Results of Source MDx's RNA Transcript-Based Six-Gene Test to Predict Survival of Castration-Resistant Prostate Cancer Patients at GU ASCO Sym - News, Search Jobs, Events".
- ↑ Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J (June 2006). "Development of an integrated prostate cancer research information system". Clin Genitourin Cancer 5 (1): 61–6. doi:10.3816/CGC.2006.n.019. PMID 16859581.
- 1 2 "HealthGrades: Awards & Recognition for Dr. William Oh, MD".